FDA approves Foundation Medicine test for Wilserdly combination therapy
- FDA approved Foundation Medicine's FoundationOne Liquid CDx as the first companion diagnostic for WILSERDLY (giredestrant) combined with everolimus.
- The test identifies adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer who may qualify for the combination.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.